Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $5.4 million.

  • Spyre Therapeutics' Interest & Investment Income rose 376.16% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 1963.18%. This contributed to the annual value of $21.3 million for FY2024, which is 24670.57% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Interest & Investment Income is $5.4 million, which was up 376.16% from $5.9 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Interest & Investment Income high stood at $6.5 million for Q1 2025, and its period low was $19000.0 during Q2 2021.
  • Over the past 5 years, Spyre Therapeutics' median Interest & Investment Income value was $420000.0 (recorded in 2023), while the average stood at $2.4 million.
  • In the last 5 years, Spyre Therapeutics' Interest & Investment Income tumbled by 8819.88% in 2021 and then surged by 159142.86% in 2024.
  • Spyre Therapeutics' Interest & Investment Income (Quarter) stood at $34000.0 in 2021, then skyrocketed by 1105.88% to $410000.0 in 2022, then soared by 906.34% to $4.1 million in 2023, then surged by 39.99% to $5.8 million in 2024, then decreased by 6.87% to $5.4 million in 2025.
  • Its Interest & Investment Income stands at $5.4 million for Q3 2025, versus $5.9 million for Q2 2025 and $6.5 million for Q1 2025.